Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Perifosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 5/20 | 0.69 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.69 |
| ▸ | TERT | O14746 | 1/20 | 0.69 |
| ▸ | UCHL3 | P15374 | 1/20 | 0.69 |
| ▸ | LPAR3 | Q9UBY5 | 10/20 | 0.46 |
| ▸ | LPAR2 | Q9HBW0 | 6/20 | 0.46 |
| ▸ | LPAR1 | Q92633 | 5/20 | 0.46 |
| ▸ | AKT2 | P31751 | 3/20 | 0.40 |
| ▸ | AKT3 | Q9Y243 | 3/20 | 0.40 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.40 |
| ▸ | PLCG2 | P16885 | 1/20 | 0.40 |
| ▸ | GAB1 | Q13480 | 1/20 | 0.40 |
| ▸ | CDC25A | P30304 | 1/20 | 0.39 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.38 |
| ▸ | P2RY10 | O00398 | 1/20 | 0.36 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14447963 | 0.99 | AKT1 (0.71) | AKT1MAPK14TERTUCHL3LPAR3 | |
| Perifosine SCHEMBL6075387 | 0.99 | AKT1 (0.71) | AKT1MAPK14TERTUCHL3LPAR3 | |
| SCHEMBL14447863 | 0.99 | AKT1 (0.71) | AKT1MAPK14TERTUCHL3LPAR3 | |
| SCHEMBL14447962 | 0.99 | AKT1 (0.71) | AKT1MAPK14TERTUCHL3LPAR3 | |
| SCHEMBL14447952 | 0.99 | AKT1 (0.71) | AKT1MAPK14TERTUCHL3LPAR3 | |
| SCHEMBL14447880 | 0.93 | AKT1 (0.64) | AKT1MAPK14TERTUCHL3LPAR3 | |
| SCHEMBL14447874 | 0.93 | AKT1 (0.64) | AKT1MAPK14TERTUCHL3LPAR3 | |
| SCHEMBL14447873 | 0.93 | AKT1 (0.64) | AKT1MAPK14TERTUCHL3LPAR3 | |
| SCHEMBL14448048 | 0.92 | AKT1 (0.62) | AKT1MAPK14TERTUCHL3LPAR3 | |
| SCHEMBL14448044 | 0.92 | AKT1 (0.62) | AKT1MAPK14TERTUCHL3LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6903080-B2 | Disease treatment with novel phospholipid derivatives | ZENTARIS GMBH (DE) | 2005-06-07 | — | — | US | disclosed |
| US-20030153533-A1 | Novel phospholipid derivatives | ZENTARIS AG | 2003-08-14 | — | — | US | disclosed |
| US-6479472-B1 | ALKYL OR ALKENE PHOSPHATES IN WHICH THE CHOLINE RADICAL IS PART OF A HETEROCYCLIC RING AS ANTIPROTOZOALS, ANTIFUNGALS, PSORIASIS TREATMENT AND FOR TREATING BONE MARROW DAMAGE DUE TO TREATMENT WITH CYTOSTATIC AGENTS | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2002-11-12 | — | — | US | disclosed |
| US-6172050-B1 | QUATERNARY AMMONIUM INTERIOR SALT CONTAINING PHOSPHATE GROUP | ASTA MEDICA AKTIENGESELLSCHAFT (DE) | 2001-01-09 | — | — | US | disclosed |
| EP-0579939-B1 | Phospholipid derivatives | ASTA MEDICA AG (DE) | 1999-02-03 | — | — | EP | disclosed |
| EP-0579939-A1 | Phospholipid derivatives | ASTA Medica Aktiengesellschaft (DE) | 1994-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153533-A1 | Novel phospholipid derivatives | PHOSPHO1, SGMS1, PLTP | AKT1 2488/4885MAPK14 2125/4885TERT 4576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.